{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'NCT #NCT03920293', 'TITLE PAGE', 'Protocol Title:', 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled,', 'Multicenter Study to Evaluate the Safety and Efficacy of', 'Ravulizumab in Complement-Inhibitor-Na\u00efv Adult Patients', 'With Generalized Myasthenia Gravis', 'Protocol Number:', 'ALXN1210-MG-306', 'Compound Number:', 'ALXN1210', 'USAN/INN:', 'Ravulizumab', 'Amendment Number:', '2', 'Short Title:', 'Safety and Efficacy Study of Ravulizumab in Adults With', 'Generalized Myasthenia Gravis', 'Sponsor Name', 'Alexion Pharmaceuticals, Inc. (Alexion)', 'Legal Registered', '121 Seaport Boulevard', 'Address:', 'Boston, MA 02210', 'USA', 'Regulatory Agency', 'IND: 140,115', 'Identifying Number:', 'EUDRACT: 2018-003243-39', 'Approval Date:', '25 Oct 2019', 'Page 1 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Sponsor Signatory:', 'PPD', '10/28/2019', 'Date', 'Medical Monitor Name and Contact Information can be found in the Study Contact list', 'distributed to Study Sites.', '24-hour Emergency Contact:', 'PPD', 'Page 2 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', \"INVESTIGATOR'S AGREEMENT\", 'I have read the ALXN1210-MG-306 study protocol and agree to conduct the study in accordance', 'with this protocol, all applicable government regulations, the principles of the ICH E6', 'Guidelines for Good Clinical Practice, and the principles of the World Medical Association', 'Declaration of Helsinki. I also agree to maintain the confidentiality of all information received or', 'developed in connection with this protocol.', 'Printed Name of Investigator', 'Signature of Investigator', 'Date', 'Page 3 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}